Scarica l'app Stockscreener
167.91
1.30%
2.15
Pre-mercato:
167.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$165.76
Aprire:
$167.17
Volume 24 ore:
1.39M
Relative Volume:
0.58
Capitalizzazione di mercato:
$35.49B
Reddito:
$398.11M
Utile/perdita netta:
$-1.03B
Rapporto P/E:
-29.44
EPS:
-5.7032
Flusso di cassa netto:
$-868.57M
1 W Prestazione:
+2.42%
1M Prestazione:
+15.99%
6M Prestazione:
+131.12%
1 anno Prestazione:
+125.26%
Intervallo 1D:
$163.42
$168.22
Intervallo di 1 settimana:
$161.19
$168.22
Portata 52W:
$60.40
$168.22
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
167.91 | 35.04B | 398.11M | -1.03B | -868.57M | -5.7032 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.10 | 106.87B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
491.22 | 63.14B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.77 | 61.27B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
849.46 | 51.94B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Is Insmed Incorporated (IM8N) stock among top earnings playsTrade Performance Summary & Low Drawdown Investment Ideas - newser.com
Insmed Incorporated stock volume spike explainedJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Why Insmed Incorporated (IM8N) stock is listed among top recommendationsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
How to build a custom watchlist for Insmed IncorporatedMarket Performance Report & Free Expert Approved Momentum Trade Ideas - newser.com
Will Insmed Incorporated (IM8N) stock see valuation expansionMarket Performance Summary & Consistent Profit Trading Strategies - newser.com
Insmed Inc stock reaches 52-week high at 167.0 USD By Investing.com - Investing.com Canada
Insmed Inc stock reaches 52-week high at 167.0 USD - Investing.com
Insmed Incorporated (INSM): Analyst Consensus Signals Strong Growth Potential Amid Biotech Innovations - DirectorsTalk Interviews
How to interpret RSI for Insmed Incorporated stock2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
What indicators show strength in Insmed IncorporatedJuly 2025 Market Mood & Real-Time Stock Movement Alerts - newser.com
What moving averages say about Insmed Incorporated2025 Investor Takeaways & Verified Trade Idea Suggestions - newser.com
Volatility clustering patterns for Insmed IncorporatedInsider Selling & Fast Gain Swing Alerts - newser.com
Short Covering: Why Insmed Incorporated stock could benefit from AI revolutionPortfolio Gains Summary & Safe Capital Growth Tips - nchmf.gov.vn
How Insmed Incorporated stock reacts to Fed rate cutsPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com
Is Insmed Incorporated trending in predictive chart modelsMarket Performance Summary & Real-Time Stock Entry Alerts - newser.com
Retail Surge: Can Insmed Incorporated stock hit analyst price targets2025 Major Catalysts & AI Driven Price Predictions - nchmf.gov.vn
Why Insmed Incorporated stock attracts global investorsWeekly Stock Summary & Fast Moving Stock Watchlists - nchmf.gov.vn
Why Insmed Incorporated stock could benefit from AI revolutionMarket Growth Summary & Safe Capital Allocation Plans - nchmf.gov.vn
Should Insmed’s (INSM) EMA Nod for BRINSUPRI Prompt a Fresh Look at Its Growth Prospects? - Yahoo Finance
EMA Backs Insmed’s Brinsupri And Sanofi’s Wayrilz, Rejects Rezurock - Citeline News & Insights
Sanofi, Insmed among winners of CHMP recommendations (SNY) - Seeking Alpha
Insmed Says Non-Cystic Fibrosis Bronchiectasis Treatment Recommended for EU Approval - MarketScreener
Insmed (INSM) Receives Positive EMA Recommendation for BRINSUPRI - GuruFocus
Insmed Incorporated CHMP Recommends EU Approval of Brinsupri (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - MarketScreener
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - PR Newswire
What institutional flow reveals about Insmed IncorporatedPortfolio Risk Summary & Daily Entry Point Alerts - newser.com
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 - PR Newswire
Is a relief rally coming for Insmed Incorporated holdersJuly 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
What dividend safety score for Insmed Incorporated stockPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Does Insmed Incorporated (INSM) Have a Promising Pipeline? - Yahoo Finance
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 - MarketScreener
Q3 2025 Results on Oct. 30 — Insmed Schedules Investor Call; Live Webcast & Replay - Stock Titan
This Is What Whales Are Betting On Insmed - Sahm
Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come - Bloomberg.com
UBS Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Can Insmed Incorporated hit a new high this monthMarket Performance Summary & Daily Entry Point Alerts - newser.com
Insmed, Inc. Hits New 52-Week High of $166.44, Up 173.69% - Markets Mojo
UBS Raises Price Target for Insmed (INSM) Following Consistent " - GuruFocus
Insmed stock price target raised to $194 from $140 at UBS on new indications - Investing.com Canada
UBS Adjusts Insmed Price Target to $194 From $140, Maintains Buy Rating - MarketScreener
Key metrics from Insmed Incorporated’s quarterly dataJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.69%
7.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):